Skip to content

Share Buybacks at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$221M
PDE
Pro-Dex, Inc.PDEX
$601K-31.4%
CONMED logo
CONMEDCNMD
$6.2M
Anika Therapeutics logo
Anika TherapeuticsANIK
$853K
Globus Medical logo
Globus MedicalGMED
$0-100%
Medtronic logo
MedtronicMDT
$435M+58.8%

Other financials

Income statement

See full
Revenue$2.1B+9.3%
Gross profit$1.5B+11.1%
Operating income$373.2M+27.7%
Net income$238.1M+30.8%
EPS (diluted)$1.22+34.1%

Balance sheet

See full
Cash & equivalents$424.2M-69.4%
Total debt$7.5B+4.1%
Total equity$12.7B+2.2%
Total assets$22.7B+2.4%

Cash flow

See full
Operating cash flow$359.4M-6.1%
CapEx$36.3M-18.6%
Free cash flow$323.1M-4.5%

Valuation

See full
Market cap$18.52B-1.4%
Enterprise value$25.57B-0.9%
P/E24.3×+1.5×
P/S2.2×-0.2×

Profitability

See full
Gross margin70%-1.0pp
Operating margin14%-3.0pp
Net margin9.1%-2.8pp
FCF margin17.3%-1.6pp

Returns & leverage

See full
Return on equity6.1%-1.2pp
Debt / equity0.6×0.0×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Zimmer Biomet Holdings in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Zimmer Biomet Holdings’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zimmer Biomet Holdings's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zimmer Biomet Holdings's share buybacks?
Zimmer Biomet Holdings (ZBH) reported share buybacks of $250.1M in Q1 2026.
How has Zimmer Biomet Holdings's share buybacks changed year-over-year?
Zimmer Biomet Holdings's share buybacks increased by 8.8% year-over-year, from $229.8M to $250.1M.
What is the long-term trend for Zimmer Biomet Holdings's share buybacks?
Over 3 years (2022 to 2025), Zimmer Biomet Holdings's share buybacks has grown at a 56.8% compound annual growth rate (CAGR), from $126.4M to $487M.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.